ImmusanT plots celiac disease vaccine; NY doc pleads guilty to larceny;

Vaccine Research

A new Cambridge, MA-based biotech, ImmusanT, plans to focus its efforts on an immunotherapeutic vaccine for celiac disease, an autoimmune disorder caused by gluten intolerance. The vaccine candidate is called Nexvax2. Item

Inovio Pharmaceuticals has reached a deal with OncoSec Medical to sell Inovio's electroportation delivery technology to the San Diego-based company. The finances of the deal were not disclosed. Article

Vaccine Market

A New York physician plead guilty to fourth-degree larceny for selling vaccines to patients that he had received for free from the state. Dr. Ghulam Mustafa has agreed to pay $179,000 to the state and faces up to four years in prison. Report

Four infants have died and five are critically ill in India after receiving a measles vaccine from Indian Immunologicals as part of a government vaccination drive. The children had received the vaccine 15 minutes prior to death. Report

Medicago has recieved its second milestone payment as part of a DARPA grant signed in August 2010. The $3.8 million payment is part of an overall $21 million grant to construct a cGMP facility in Research Triangle Park, NC. Article

The UK's Health Protection Agency announced that a hepatitis B vaccine program in English and Welsh prisons has led to a reduction in overall hepatitis B prevalence among inmates--from 30 percent to 17 percent. There was also a 300 percent uptick in the number of vaccinations in 2009 compared to 2003. News

Suggested Articles

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.